NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT (NSABP) Web link

The National Surgical Adjuvant Breast and Bowel Project (NSABP) conducts clinical trials in breast and colorectal cancer at hundreds of locations around the country.In addition to treatment trials, NSABP conducts large prevention trials including the STAR trial (Study of Tamoxifen and Raloxifene). Established over 40 years ago, NSABP now conducts research at nearly 200 medical centers, university hospitals, large oncology practice groups and health maintenance organizations in the United States, Canada, Puerto Rico and Australia. Those sites and their satellites include more than 5,000 physicians, nurses and other medical professionals who have enrolled more than 60,000 women and men in clinical trials in breast and colorectal cancer since the inception of the organization.

Open Breast Cancer Protocols

NSABP-B-34;CTSU
Phase III Randomized Study of Adjuvant Clodronate with or without Systemic Chemotherapy and/or Tamoxifen in Women with Early-Stage Breast Cancer Protocol

NSABP-B-30;CTSU
Phase III Randomized Study of Adjuvant Doxorubicin and Cyclophosphamide Followed by Docetaxel Versus Doxorubicin and Docetaxel Versus Doxorubicin, Docetaxel and Cyclophosphamide in Women with Breast Cancer and Positive Axillary Nodes Protocol

NSABP-B-31
Phase III Randomized Study of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with or without Trastuzumab (Herceptin) in Women with Node-Positive Breast Cancer That Overexpresses HER2 Protocol

NSABP-B-33; CTSU
Phase III Randomized Study of Exemestane in Postmenopausal Women with Resected Stage I,II or IIIA Breast Cancer Who Have Completed Five Years of Tamoxifen Protocol

NSABP-B-32
Phase III Randomized Study of Sentinel Node Dissection with or without Conventional Axillary Dissection in Women with Clinically Node-Negative Breast Cancer Protocol

NSABP-P-2
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer Protocol

Contact Information
Operations Center
East Commons Professional Building
Four Allegheny Center -5th Floor
Pittsburgh, PA 15212-5234
Phone:(412) 330-4600, Fax:(412) 330-4660

Biostatistical Center
One Sterling Plaza
201 North Craig Street, Suite 500
Pittsburgh, PA 15213
Phone:(412) 624-2666,Fax:(412) 624-1082

RADIATION THERAPY ONCOLOGY GROUP (RTOG) Web link

The Radiation Therapy Oncology Group (RTOG) conducts clinical trials employing radiotherapy alone and in combination with other modalities (such as surgery and/or chemotherapy) as well as different radiotherapeutic modalities such as implantation (brachytherapy), radiosurgery and three-dimensional conformal treatment planning. Headquartered in Philadelphia, RTOG is comprised of 250 major research institutions nationally and in Canada. With almost 30 years of experience, RTOG currently has 40+active studies.

Open Breast Cancer Protocols

RTOG-9714; NCI-P97-0124
Phase III Randomized Study of Palliative Radiation Therapy for Bone Metastases from Breast or Prostate Cancer Protocol

RTOG-9804; CTSU; RTOG-DEV-1026
Phase III Randomized Study of Tamoxifen with or without Radiotherapy in Women with Ductal Carcinoma In Situ (DCIS) of the Breast Protocol

Contact Information
RTOG
1101 Market Street,14th Floor
Philadelphia, PA 19107
Phone:(215) 574-3205
Fax:(215) 928-0153
Tim McKeough, RTOG Group Administrator
E-mail:tmckeough@phila.acr.org

SOUTHWEST ONCOLOGY GROUP (SWOG) Web link

The Southwest Oncology Group (SWOG) conducts clinical trials and basic research in the prevention and cure of cancer in adults.Headquartered in Texas, the group consists of almost 4,000 physicians at 283 institutions throughout the United States and Canada. Since its inception in 1956, SWOG has enrolled more than 150,000 in clinical trials.

Open Breast Cancer Protocols

SWOG-S0102
Phase II Study of Docetaxel,Vinorelbine and Filgrastim (G-CSF)in Women with HER-2 Negative Stage IV Breast Cancer Protocol

CAN-NCIC-MA17; CLB-49805; EORTC-10983; JRF-Vor-Int-10; NCCTG-CAN-MA17; SWOG-CAN-MA17
Phase III Randomized Study of Letrozole Versus Placebo in Women with Primary Breast Cancer Who Have Completed at Least Five Years of Adjuvant Tamoxifen Protocol

SWOG-S9630; SWOG-9630
Phase III Randomized Study of Medroxyprogesterone Acetate and Observation for Prevention of Endometrial Pathology in Patients with Postmenopausal Breast Cancer Treated with Adjuvant Tamoxifen Protocol

SWOG-S0012; CTSU
Phase III Randomized Study of Neoadjuvant Doxorubicin and Cyclophosphamide with or without Filgrastim (G-CSF) in Women with Inflammatory or Estrogen Receptor-Negative Locally Advanced Breast Cancer Protocol

SWOG-S9927; GUMC-00223
Phase III Randomized Study of Postmastectomy Radiotherapy in Women with Stage II Breast Cancer with One to Three Positive Nodes Protocol

SWOG-S9905
Phase III Randomized Study of Zoledronate as Adjuvant Therapy in Patients with Stage I,II or IIIA Nonmetastatic Breast Cancer Protocol

SWOG-9342
Companion Study to Evaluate Late Cardiac Effects in Women with Node-Negative Breast Cancer Receiving Adjuvant Chemotherapy on Protocol SWOG-8897 Protocol

Contact Information
SWOG
14980 Omicron Drive
San Antonio, TX 78245-3217
Phone:(210) 677-8808, Fax:(210) 677-0006

Select Publications

Page 6 of 6
Previous Page

Home · Search